Background: Medication Possession Ratio (MPR) measures adherence and persistence on anti-obesity medication (AOM). Previous studies have shown poor compliance to AOM. An MPR of 80% historically suggests acceptable level of adherence. The aim of our study was to illustrate MPR rate in our MOVE! Program at VA Greater Los Angeles Healthcare System (VAGLAHS). Methods: Patients were identified if they filled any FDA approved AOM (phentermine/topiramate, naltrexone/bupropion, orlistat, liraglutide, or lorcaserin) from January 2006 to June 2020. Patients were excluded if they only filled AOM once. MPR was calculated as the sum of day supply of medication for all fills over number of days from first fill to last fill. Data was extracted from VAs Corporate Data Warehouse. Results: A total of 280 Veterans were included in our MPR calculation. MPR for orlistat was the least at 56% (n=160, range 5-200%), followed by low dose phentermine/topiramate at 76% (n=97, range 15-130%), liraglutide at 82% (n=73, range 35-153%), high dose phentermine/topiramate at 83% (n=38, range 17-162%), lorcaserin at 85% (n=35, range 33-120%), and lastly naltrexone/bupropion with the highest MPR at 92% (n=16, range 34-200%). Average days between first and last fill in order from shortest to longest duration were 184 days on naltrexone/bupropion, 249 days on lorcaserin, 323 days on high dose phentermine/topiramate, 333 days on low dose phentermine/topiramate, 364 days on liraglutide, and 445 days on orlistat. Conclusions: There were varying ranges of MPR of each medication, however we saw a high percentage of adherence, which would conflict with existing poor adherence studies, except for orlistat, in our MOVE! Program at our institution. We had a relatively long duration of therapy as well on AOMs suggesting efficacy and tolerability as we move forward in treating obesity as a chronic disease state.